Acceleron Pharma Inc (NASDAQ:XLRN) Sellers Reduced Their Shorts By 0.07% As Of Jun 29, 2018

June 29, 2018 - By Madeline Delgado

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During Q1 2018 the big money sentiment increased to 1.27. That’s change of 0.18, from 2017Q4’s 1.09. 13 investors sold all, 39 reduced holdings as Acceleron Pharma Inc. ratio is positive. 42 increased positions while 24 funds bought positions. Funds hold 38.30 million shares thus 0.44% more from 2017Q4’s 38.14 million shares.
Qvt Financial Limited Partnership invested in 373,481 shs. Northern Tru Corporation reported 0% stake. Schwab Charles Inv Mgmt Inc owns 192,271 shs. Ameritas Invest Partners Inc owns 3,252 shs. Pnc Service Group holds 0.01% or 131,119 shs in its capital. Natl Bank Of New York Mellon reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Brown Advisory has 296,383 shs. State Board Of Administration Of Florida Retirement Sys accumulated 19,011 shs or 0% of the stock. Waddell And Reed Fin Incorporated accumulated 28,300 shs or 0% of the stock. Us Savings Bank De reported 500 shs. Sei, a Pennsylvania-based fund reported 300 shs. Jane Street Group Ltd Company accumulated 6,404 shs. Citadel Advisors Ltd Llc invested in 0% or 160,515 shs. The California-based Jasper Ridge Prns L P has invested 0.03% in Acceleron Pharma Inc. (NASDAQ:XLRN). Vanguard Grp has 2.50M shs.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 buys and 12 insider sales since January 2, 2018. $182,363 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Kumar Ravindra. Rovaldi Christopher sold $134,395 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 3,500 shs on Tuesday, April 3. On Tuesday, March 6 POPS RICHARD F sold $1.55M worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 37,500 shs. Quisel John D sold $46,232 worth of stock or 1,204 shs. Shares for $814,848 were sold by MCLAUGHLIN KEVIN F on Tuesday, January 2.

Acceleron Pharma Inc (NASDAQ:XLRN) noted a decrease of 0.07% in shares shorted. FINRA announced shares shorted of XLRN’s total 2.73M shares. That’s 0.07% down from 2.73 million shares. Acceleron Pharma Inc (NASDAQ:XLRN) has 280,800 shares average volume. It’ll cost 10 days for XLRN to restore its former position. Acceleron Pharma Inc float short is 7.08%.

XLRN touched $48.536 during the last trading session after $14.556 change.Acceleron Pharma Inc. has 3.09 million shares volume, 843.92% up from normal. XLRN is uptrending and has moved 37.77% since June 29, 2017. XLRN outperformed the S&P500 by 25.20%.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The company has $2.22 billion market cap. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Currently it has negative earnings. The company??s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

In total 5 analysts cover Acceleron Pharma (NASDAQ:XLRN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. 80% are bullish. 7 are the (NASDAQ:XLRN)’s analyst reports since January 8, 2018 according to StockzIntelligence Inc. The company rating was maintained by H.C. Wainwright on Wednesday, February 28. On Tuesday, May 22 the rating was initiated by Oppenheimer with “Hold”. The company rating was maintained by Barclays Capital on Wednesday, February 28. On Monday, January 8 the rating was initiated by H.C. Wainwright with “Buy”. On Monday, February 26 the firm earned “Overweight” rating by JP Morgan. On Thursday, March 1 the stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Buy” rating by Citigroup. On Wednesday, March 28 H.C. Wainwright initiated the shares of XLRN in report with “Buy” rating.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news brought out briefly go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Streetinsider.com or 247Wallst.com. The titles are as follows: “Acceleron: Luspatercept New Data Is A Buy Signal” brought out on June 07, 2018, “10 Biggest Price Target Changes For Friday” on June 29, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with a publish date: June 29, 2018, “Acceleron Pharma (XLRN) Highlights Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia” and the last “Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM …” with publication date: June 29, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.